Satellos Bioscience Inc.

Recent News

  • Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration

    Toronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) (Satellos" or the "Company"), a regenerative medicine company focused on the treatment of Duchenne muscular dystrophy and other degenerative or muscle wasting disorders, is pleased to announce that the Company's board of directors has appointed J. Robert Hall, CFA as Vice-President, Finance & Administration.Mr. Hall has been with Satellos since January of 2020, serving in various finance and administration related roles. In his new role he will...

    2021-09-17 8:00 AM EDT
  • Satellos Bioscience Announces Evidence for Regeneration in Severe Model of Duchenne

    Toronto, Ontario--(Newsfile Corp. - September 13, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), a regenerative medicine company focused on the treatment of degenerative muscle disorders, announced today core findings from additional preclinical drug development studies in their lead program to treat Duchenne muscular dystrophy ("Duchenne"). Satellos scientists are developing small molecule drugs with the goal of restoring faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative and age-related muscle disorders. ...

    2021-09-13 7:00 AM EDT
  • Satellos Bioscience Announces Partnership with Jesse's Journey

    Toronto, Ontario--(Newsfile Corp. - September 7, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), and Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, are proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne.Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate...

    2021-09-07 7:00 AM EDT
  • Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A

    Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics Inc. ("iCo"), today filed financial results and MD&A reports for the second quarter which ended on June 30, 2021, on SEDAR. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards.Satellos is developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne muscular dystrophy and potentially other degenerative muscle...

    2021-08-30 5:43 PM EDT
  • Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target

    Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy ("Duchenne").Satellos scientists are developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate the activity of PTP-X, the codename for an enzyme which Satellos...

    2021-08-27 7:00 AM EDT
  • Satellos Bioscience Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBD

    Toronto, Ontario--(Newsfile Corp. - August 18, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics, Inc., and NW PharmaTech Limited ("NW PharmaTech") announced today that Amphotericin B Technologies, Inc. ("AmpB Tech"), a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology ("OralTransTM"), has entered into a Joint Development Agreement with NW PharmaTech to develop an oral formulation of cannabidiol ("CBD") for the over-the-counter market. Oral CBD will initially target the...

    2021-08-18 4:05 PM EDT
  • Satellos and iCo Announce Completion of Reverse Takeover

    Toronto, Ontario--(Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following the receipt of the final order of the Supreme Court of British Columbia on August 5, 2021, and subject to the final approval of the TSX Venture Exchange (the "TSXV"), of the previously announced reverse takeover transaction which was completed by way of plan of arrangement under Section 192 the Canada Business Corporations Act...

    2021-08-13 6:28 PM EDT
  • iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.

    Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that at an annual and special meeting of the Company held on August 3, 2021, shareholders of the Company have approved, among other matters, iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").The Company expects trading of the shares of the combined company to begin trading on the TSX Venture Exchange as Satellos Bioscience...

    2021-08-05 5:32 PM EDT